Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

192.44USD
5:39pm GMT
Change (% chg)

$1.13 (+0.59%)
Prev Close
$191.31
Open
$191.93
Day's High
$192.73
Day's Low
$191.13
Volume
400,944
Avg. Vol
1,333,318
52-wk High
$210.18
52-wk Low
$163.31

Select another date:

Tue, Feb 26 2019

Photo

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

UPDATE 2-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Feb 25 Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

CORRECTED-UPDATE 1-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug -report

Feb 25 A U.S. jury said on Monday that patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

CORRECTED-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Feb 25 A U.S. jury on Monday said patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

NEW YORK Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

NEW YORK Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

Sanofi and Regeneron cut list price of cholesterol drug by 60 pct

NEW YORK, Feb 11 Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

Amgen 2019 forecast falls short of expectations, shares dip

Amgen Inc on Tuesday reported fourth-quarter profit that easily surpassed expectations as sales rose and tax expense fell, but competition for its older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

Amgen 2019 forecast falls short of expectations, shares dip

Amgen Inc on Tuesday reported fourth-quarter profit that easily surpassed expectations as sales rose and tax expense fell, but competition for its older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

Select another date: